Data sheet
| Specificity | This kit is validated to be used for quantification of human IgG1, IgG2, IgG3, and IgG4 in blood samples from human, monkey, rodent, porcine, etc. |
| Background | Monoclonal antibody therapy has been proved beneficial for cancer, autoimmune diseases, and neurological disorders that result in the degeneration of body cells, such as Alzheimer's disease. Before the humanized IgGs are used as drug in human patients, large amount of preclinical testing with experimental animals like monkey, rodent and other animals are carried out for PK/PD and ADME parameter testing. Due to the sequence similarity, the recombinant humanized IgG has to be quantified with an IgG ELISA kit with high human IgG specificity. NovateinBio's therapeutic IgG ELISA kit is designed to meet this research and developmental application needs. |
| Sample Type | Serum, plasma, milk, urine, CSF, tissue or cell extract |
| Assay Range | 0.625 ng/ml - 40 ng/ml |
More info
|
|
Intra-Assay Precision |
Inter-Assay Precision |
|||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
|
n |
20 |
20 |
20 |
20 |
20 |
20 |
|
|
CV (%) |
5.3% |
5.1% |
5.7% |
10.1% |
9.5% |
10.4% |
|
|
Average CV (%) |
5.4% |
10.0% |
|||||
Recovery
|
Standard Added Value |
1.25 – 20 ng/ml |
|
|
Recovery % |
92 – 111% |
|
|
Average Recovery % |
98% |
Cross-reactivity
|
Species |
Cross-Reactivity (%) |
|
|
Canine |
None |
|
|
Bovine |
None |
|
|
Monkey |
None |
|
|
Mouse |
None |
|
|
Rat |
None |
|
|
Swine |
None |
|
|
Rabbit |
None |
Please email to techsupport@novateinbio.com for manual.
Introduction:
Immunoglobulin G (IgG) antibodies are large heterodimeric molecules, approximately 150 kDa and are composed of two kinds of polypeptide chain, called the heavy (~50kDa) and the light chain (~25kDa). The two types of light chains are kappa (κ) and lambda (λ). By cleavage with enzyme papain, the Fab (fragment-antigen binding) part can be separated from the Fc (fragment constant) part of the molecule. The Fab fragments contain the variable domains, which consist of three antibody hypervariable amino acid domains responsible for the antibody specificity embedded into constant regions. The four known IgG subclasses are involved in antibody-dependent cellular cytotoxicity.
Monoclonal antibody therapy has been proved beneficial for cancer, autoimmune diseases, and neurological disorders that result in the degeneration of body cells, such as Alzheimer's disease. Monoclonal antibody therapy can aid the immune system because the innate immune system responds to the environmental factors it encounters by discriminating against foreign cells from cells of the body. Therefore, tumor cells that are proliferating at high rates, or body cells that are dying which subsequently cause physiological problems are generally not specifically targeted by the immune system, since tumor cells are the patient's own cells. Tumor cells, however, are highly abnormal, and many display unusual antigens. Some such tumor antigens are inappropriate for the cell type or its environment. Monoclonal antibodies can target tumor cells or abnormal cells in the body that are recognized as body cells, but are debilitating to one's health.
Before the humanized IgGs are used as drug in human patients, large amount of preclinical testing with experimental animals like monkey, rodent and other animals are carried out for PK/PD and ADME parameter testing. Due to the sequence similarity, the recombinant humanized IgG has to be quantified with an IgG ELISA kit with high human IgG specificity. NovateinBio's therapeutic IgG ELISA kit is designed to meet this research and developmental application needs.